Catenaa, Friday, September 04, 2026- Oura filed for a US IPO on Thursday, disclosing that revenue surged 74% year over year as losses widened.
The company reported $1.21 billion in revenue for the nine months ended June 30, a 74% jump from $697.6 million during the same stretch the prior year.
Its net loss attributable to stockholders totaled $924.3 million over that span, more than four times the $182.8 million loss recorded in the year-ago period.
According to the filing, those losses reflect a deemed dividend paid to certain holders of redeemable convertible preferred stock.
Oura sold approximately 3.6 million rings in the past year and had more than five million paid subscribers as of June 30, the filing shows.
The Oura Ring 5 retails for $399, or $499 for premium finishes, and membership plans in the US are priced at $5.99 per month or $69.99 per year.
According to Bloomberg, the IPO could generate up to $3 billion for Oura and certain of its investors while putting the company’s valuation above $16 billion.
The filing identifies Goldman Sachs, Morgan Stanley, JPMorgan, Allen, and Jefferies Financial Group as the underwriters managing the deal. Oura intends to list its shares on the Nasdaq Global Select Market, where they will trade under the ticker OURA.
The filing identifies Fidelity Management and Research, Forerunner Ventures, Bedford Ridge Capital, and Lifeline Ventures as shareholders each holding a stake of 5% or more.
The company, founded in Finland in 2013, filed a draft IPO prospectus with the SEC confidentially in May, with no timeline given at that time for a public offering.
In its earlier filing, Oura said paid membership was expected to exceed five million that quarter and that cumulative ring sales had topped 5.5 million units.
The company has previously said it generated roughly $1 billion in revenue in 2025 and expected to approach $2 billion in 2026.
Oura is also contending with legal pressure ahead of its debut. The company faces a proposed class-action lawsuit alleging its ring cannot accurately measure sleep stages, with the complaint claiming the device’s estimates are little more reliable than chance.
Oura has disputed the allegations and said it will defend against the claims, according to TechCrunch.
In its filing, Oura said it has accumulated nearly 42 billion hours of physiological data, which it uses to power AI and machine-learning models across its platform.
